Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients

Haematological, immunophenotypic and cytogenetic characteristics were analysed in 241 patients with acute myeloid leukaemia (AML) M0, including 58 children. Children < 3 years and adults between 60 and 70 years of age were most frequently affected. Immunophenotyping showed a heterogeneous phenotype. Anti‐myeloperoxidase was positive in about half of the patients. Cytogenetic data were available from 129 (54%) patients. A normal karyotype was found in only 24%. Most of the abnormalities were unbalanced and the chromosomes 5, 7, 8 and 11 were the most frequently affected. Survival data were available from 152 treated patients (63%). The median overall survival for all patients was 10 months, 20 months for children (n = 36), 10 months for the young adult group (n = 50) and 7 months for the elderly patients (n = 66) (P = 0·09). Karyotype was not a prognostic factor influencing survival. AML M0 shows the immunological characteristics of early progenitor cells, but the expression of the different markers and cytogenetic abnormalities is heterogeneous. The prognosis is poor compared with other de novo AML and similar to that of AML with multilineage dysplasia or AML following myelodysplastic syndromes.

[1]  J. Rowley,et al.  Associations between morphology, karyotype, and clinical features in myeloid leukemias. , 1987, Human pathology.

[2]  M. B. van 't Veer,et al.  AML-MO: clinical entity or waste basket for immature blastic leukemias? A description of 14 patients. Dutch Slide Review Committee of Leukemias in Adults. , 1995, Annals of hematology.

[3]  A Orfao,et al.  Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). , 1995, Leukemia.

[4]  Segeren Cm,et al.  AML-MO: clinical entity or waste basket for immature blastic leukemias? A description of 14 patients. Dutch Slide Review Committee of Leukemias in Adults. , 1995 .

[5]  W. Tsay,et al.  Minimally differentiated acute myeloid leukemia in Taiwan: predominantly occurs in children less than 3 years and adults between 51 and 70 years , 1999, Leukemia.

[6]  A. Órfão,et al.  The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). , 1998, Blood.

[7]  J. Testa,et al.  Minimally differentiated acute nonlymphocytic leukemia: a distinct entity. , 1987, Blood.

[8]  E. Paietta.  Proposals for the immunological classification of acute leukemias. , 1995, Leukemia.

[9]  J. Reuben,et al.  Heterogeneity in acute undifferentiated leukemia. , 1988, Hematologic pathology.

[10]  C. E. van der Schoot,et al.  Monoclonal antibodies against myeloperoxidase are valuable immunological reagents for the diagnosis of acute myeloid leukaemia , 1990, British journal of haematology.

[11]  M. Sanz,et al.  Acute myeloblastic leukemia with minimal myeloid differentiation (FAB AML-M0): a study of eleven cases. , 1993, Leukemia & lymphoma.

[12]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  D. Treille,et al.  Surface marker expression in adult acute myeloid leukaemia: correlations with initial characteristics, morphology and response to therapy , 1989, British journal of haematology.

[14]  D. Neuberg,et al.  Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: the Eastern Cooperative Oncology Group experience , 1998, Leukemia.

[15]  D. Campana,et al.  Phenotypic, genotypic, cytochemical, and ultrastructural characterization of acute undifferentiated leukemia. , 1990, Leukemia.

[16]  G. Papa,et al.  Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0). , 1994, Blood.

[17]  G. Dewald,et al.  Acute myeloid leukemia with minimal differentiation. A multiple parameter study. , 1998, American journal of clinical pathology.

[18]  G. Papa,et al.  Minimally differentiated acute myeloid leukemia (AML-M0): comparison of 25 cases with other French-American-British subtypes. , 1997, Blood.

[19]  The Relation between Morphology and Other Features of Acute Myeloid Leukaemia, and their Prognostic Significance: Report of the Medical Research Council's Working Party on Leukaemia in Adults , 1975 .

[20]  D. Olive,et al.  The immunophenotype of minimally differentiated acute myeloid leukemia (AML-M0): reduced immunogenicity and high frequency of CD34+/CD38− leukemic progenitors , 1999, Leukemia.

[21]  T. Tsuruo,et al.  Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. , 1992, Blood.

[22]  A. Kuramoto,et al.  ACUTE UNCLASSIFIABLE LEUKAEMIA IN ADULTS, DEMONSTRATING MYELOID ANTIGENS AND MYELOPEROXIDASE PROTEIN , 1988, British journal of haematology.

[23]  B. Dörken,et al.  Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics , 1999, Leukemia.

[24]  Determination of ultrastructural peroxidases and immunologic membrane markers in the diagnosis of acute leukemias. , 1982 .

[25]  R. Zittoun,et al.  Determination of ultrastructural peroxidases and immunologic membrane markers in the diagnosis of acute leukemias. , 1982, Blood.

[26]  D. Catovsky,et al.  The role of ultrastructural cytochemistry and monoclonal antibodies in clarifying the nature of undifferentiated cells in acute leukaemia , 1988, British journal of haematology.

[27]  J. Visser,et al.  Purification of pluripotent hemopoietic stem cells: past and present. , 1990, Experimental hematology.

[28]  J. Harbott,et al.  Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. , 1995, Blood.

[29]  J. Jelinek,et al.  Three cases of near-tetraploid acute myeloid leukemias originating in pluripotent myeloid progenitors. , 1998, Leukemia research.

[30]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .

[31]  H. Gralnick,et al.  Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML‐MO) , 1991, British journal of haematology.

[32]  M. Tomonaga,et al.  Minimally differentiated acute myeloid leukemia (AML-M0) with extensive erythrophagocytosis and del(20)(q11) chromosome abnormality. , 2000, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

[33]  P. Cin,et al.  Cytogenetic profile of minimally differentiated (FAB M0) acute myeloid leukemia: correlation with clinicobiologic findings. , 1995, Blood.

[34]  J. Bennett,et al.  Acute Leukemia Cytochemical Profile: Diagnostic and Clinical Implications , 1975 .

[35]  A. Órfão,et al.  The Reliability and Specificity of c-kit for the Diagnosis of Acute Myeloid Leukemias and Undifferentiated Leukemias , 1998 .

[36]  E. Montserrat,et al.  Acute myeloblastic leukemia with minimal myeloid differentiation: phenotypical and ultrastructural characteristics , 1998, Leukemia.

[37]  M. Tribalto,et al.  Minimally differentiated acute myeloid leukaemia (AML‐MO): cytochemical, immunophenotypic and cytogenetic analysis of 19 cases , 1994, British journal of haematology.

[38]  A Orfao,et al.  Impact of immunophenotyping on management of acute leukemias. , 1999, Haematologica.